Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
380 hedge funds and large institutions have $2.42B invested in Catalyst Pharmaceutical in 2025 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 125 increasing their positions, 128 reducing their positions, and 45 closing their positions.
49% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 45
20% more capital inflows, than outflows
Capital inflows: $224M | Capital outflows: $186M
4% more funds holding
Funds holding: 364 → 380 (+16)
0.15% more ownership
Funds ownership: 84.42% → 84.58% (+0.15%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 128
7% less call options, than puts
Call options by funds: $2.02M | Put options by funds: $2.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$25.6M |
| 2 |
Morgan Stanley
New York
|
+$24.3M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$12M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.2M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$19.9M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$15M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$9.6M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$7.44M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.27M |
CPRX Hedge Fund Activity: Q4 2025 in Review
380 of the 8,307 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2025, worth a combined $2.42B — up 19% from $2.04B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new CPRX positions and 45 closed out — a net gain of 22 holders — while 125 added to existing stakes and 128 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $25.6M. The largest seller was Renaissance Technologies, cutting an estimated $19.9M.
- 380 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2025, up from 364 in Q3 2025.
- Funds reported $2.42B of Catalyst Pharmaceutical stock for Q4 2025, up 19% quarter-over-quarter.
- 67 funds opened new Catalyst Pharmaceutical positions in Q4 2025 and 45 closed out, a net change of +22 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2025 was Janus Henderson Group, an estimated $25.6M added.
- The largest Catalyst Pharmaceutical seller in Q4 2025 was Renaissance Technologies, an estimated $19.9M sold.
Based on aggregated 13F filings for Q4 2025.